Daratumumab is effective and safe
Gene expression analysis uncovers clues
Novel drugs included in therapy
Test helpful for SLN-negative, stage I to IIA and thin tumors
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Refractory patients respond to combination therapy
First agent in a new class of noncytotoxic cancer drugs
Data may lead to better treatment
Know Your Tumor initiative matches treatments with patients
How to care for patients with this rare, complex disease
Study includes largest cohort to date
Advertisement
Advertisement